CALA Quote, Trading Chart, Calithera Biosciences Inc.
home / stock / cala / cala quote
$2.13 Last:
3.4% Change Percent:
$2.06 Open:
$2.13 Previous Close:
$2.14 High:
$2.045 Low:
864,366 Volume:
06/24/2021 04:41:38 am Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
CALA Last Five Trading Days
| Stock Date | Open Price | Close Price | High | Low | Volume |
|---|---|---|---|---|---|
| 2021-06-24 | 2.06 | 2.13 | 2.14 | 2.045 | 864,366 |
| 2021-06-23 | 2.1 | 2.06 | 2.105 | 2.025 | 916,583 |
| 2021-06-22 | 2.05 | 2.09 | 2.12 | 1.99 | 896,654 |
| 2021-06-21 | 2.08 | 2.05 | 2.11 | 1.97 | 855,611 |
| 2021-06-18 | 2.18 | 2.08 | 2.21 | 2.06 | 1,132,401 |
| 2021-06-17 | 2.24 | 2.18 | 2.26 | 2.17 | 503,863 |
| 2021-06-16 | 2.24 | 2.22 | 2.28 | 2.1912 | 657,186 |
| 2021-06-15 | 2.32 | 2.24 | 2.34 | 2.24 | 682,506 |
| 2021-06-14 | 2.26 | 2.31 | 2.34 | 2.21 | 877,103 |
| 2021-06-11 | 2.35 | 2.28 | 2.36 | 2.25 | 662,795 |
| 2021-06-10 | 2.29 | 2.32 | 2.34 | 2.28 | 430,689 |
| 2021-06-09 | 2.24 | 2.26 | 2.37 | 2.24 | 615,609 |
| 2021-06-08 | 2.31 | 2.25 | 2.32 | 2.21 | 721,779 |
| 2021-06-07 | 2.21 | 2.28 | 2.34 | 2.21 | 783,253 |
| 2021-06-04 | 2.37 | 2.23 | 2.4522 | 2.21 | 1,160,245 |
| 2021-06-03 | 2.45 | 2.41 | 2.4882 | 2.38 | 564,735 |
| 2021-06-02 | 2.43 | 2.48 | 2.5927 | 2.4 | 1,923,207 |
| 2021-06-01 | 2.29 | 2.4 | 2.41 | 2.285 | 807,957 |
| 2021-05-31 | 2.28 | 2.28 | 2.39 | 2.27 | 550,376 |
| 2021-05-28 | 2.28 | 2.28 | 2.39 | 2.27 | 549,736 |
Calithera Biosciences Inc. Company Name:
CALA Stock Symbol:
NASDAQ Market:
Calithera Biosciences Inc. Website:
News, Short Squeeze, Breakout and More Instantly...
-
SOUTH SAN FRANCISCO, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small-molecule drugs for the treatment of cancer and other life-threatening diseases, today shared fi...
-
SOUTH SAN FRANCISCO, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced ...
-
--CB-708 is an oral small molecule inhibitor of CD73 in preclinical development for oncology --Antengene is granted exclusive rights to develop and commercialize asset discovered and initially developed by Calithera SOUTH SAN FRANCISCO, Calif. and SHANGHAI, China, May 17, 2021...